Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 6.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 325,947 shares of the medical research company's stock after selling 22,329 shares during the period. Victory Capital Management Inc. owned about 0.64% of Charles River Laboratories International worth $60,170,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. Wellington Management Group LLP lifted its position in Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock valued at $736,819,000 after acquiring an additional 3,738,018 shares during the last quarter. Mizuho Securities USA LLC increased its stake in shares of Charles River Laboratories International by 2,336.4% in the third quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company's stock worth $19,081,000 after acquiring an additional 92,895 shares during the period. Premier Fund Managers Ltd increased its stake in shares of Charles River Laboratories International by 56.3% in the third quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company's stock worth $49,573,000 after acquiring an additional 90,000 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after acquiring an additional 85,759 shares during the period. Finally, Proficio Capital Partners LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth $10,768,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares of the company's stock, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James C. Foster bought 6,075 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

CRL has been the topic of a number of research reports. Morgan Stanley cut their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. Robert W. Baird dropped their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. William Blair lowered shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. TD Cowen raised their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research report on Monday, November 11th. Finally, UBS Group restated a "neutral" rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $198.36.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL traded up $6.93 during midday trading on Friday, hitting $176.20. The company's stock had a trading volume of 1,169,106 shares, compared to its average volume of 699,906. The business's 50 day simple moving average is $169.15 and its 200 day simple moving average is $185.76. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The company has a market cap of $9.01 billion, a P/E ratio of 1,174.68, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $274.77.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company's revenue for the quarter was down 1.1% on a year-over-year basis. During the same period last year, the firm posted $2.46 earnings per share. On average, analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).